



# Perlmutter Cancer Center

An NCI-designated  
Comprehensive Cancer Center

## PCC Progress Report

February 2023



**200+**  
active therapeutic  
clinical trials

**Top 20**  
cancer hospital  
in the U.S.

Part of  
NYU Langone Health,  
**#1 in the U.S.**  
for quality and safety.

Speak to a live representative: 833-698-5722 (833-NYUL-PCC)

# PCC Today: A Snapshot

**195**

Full Members

**40**

New External Recruits

**22%**

Intra-programmatic  
collaborations

**14%**

Inter-programmatic  
collaborations

**105**

Multi-PI Projects

↑ 64% since 2017

**\$29.5M**

NCI Funding (direct, non-training)

↑ 70% since 2017

**\$90.1M**

Total Funding (Peer and Non-Peer Reviewed)

↑ 42% since 2017

# PCC Today: A Snapshot

**>400,000**

Outpatient Visits

↑ 31% since 2017

**5,229**

Manhattan Analytic Cases (2020)

↑ +6,466 at Regional Sites

**10**

Cancer-  
Relevant  
T32s

**622**

Interventional Therapeutic  
Accruals (annualized 2022)

↑ 17% since 2017

**1,157**

Interventional Accruals  
(annualized 2022)

**79**

Phase 1 DMG Accruals  
(annualized 2022)

↑ 32% since 2017

# Recent Recruits (2022)



**Marcin Imielinski, MD, PhD (CGD)**  
Weill-Cornell  
Head, Cancer Genomics



**Mark Yarmarkovich, PhD (TIM)**  
Children's Hospital of Philadelphia  
Intracellular peptide/MHC-based immune therapy

# National Recognition and Leadership Since 2012



**No. 19 in 2022**  
**No. 2 medical school for research**



**Only health system in NYC with an 'A' grade across all sites**



**5 Star rating**



**No. 1 in Ambulatory Care Quality and Accountability (2021)**



Bar-Sagi, Boeke, Chakravarti, Littman, Moore, Reinberg, Neel



Reinberg, Littman, Simeone



Carroll, Kimmelman, Neel, Philips, Wong



Littman, Pagano, Nudler, Reinberg



Chakravarti, J. Goldberg, Koide, H. Klein, Levy, Philips, Reinberg, Rom



Bar-Sagi, Boeke, Littman, Nudler, Reinberg



Academy Fellow: Bar-Sagi  
Board of Directors (Past):  
Bar-Sagi, Neel



R35 – W. Chen, Bar-Sagi, Ercan, Hubbard, Kimmelman, Maurano, Pagano, Rothenberg, Schlick, Skok, D. Smith, Zhang



Executive Committee & Vice Chair,  
ALL Committee: Raetz



Affiliate Organization (AO) of Dana-Farber  
Harvard Cancer Center ET-CTN Lead  
Academic Organization (LAO)



Novartis FIH (First-in-Human) Site



Society for Thoracic Surgeons  
3 Star rating (Lobectomy)




NPF Center of Excellence  
(Clinical & Academic)



Team Award '21 Best in Class (Non-Technical)



# Emerging National Leadership



**Robert Banh, PhD (CCB)**  
2022 Damon Runyon-Dale F. Frey Award  
for Breakthrough Scientists

---



**Carlos Carmona-Fontaine, PhD (TIM)**  
2020 Pew Scholar

---



**Weiqiang Chen, PhD (TIM)**  
2021 Cellular and Molecular Bioengineering  
Rising Star Award

---



**Teresa Davoli, PhD (CGD)**  
2018 V Foundation Scholar Award,  
2021 MRA Young Investigator Award

---



**Gilad Evrony, MD, PhD (CGD)**  
2020 Pew Scholar, NIH Director's Early  
Independence Award (2019)



**Liam Holt, PhD (CCB)**  
2019 Pershing Square Sohn Prize  
ACS Bailey Foundation Research Scholar (2019)

---



**Mayumi Ito, PhD (CCB)**  
2021 DoD Medical Research Program  
Mid Career Accelerator Award

---



**Amanda Lund, PhD (TIM)**  
2022 AACR-Bristol Myers Squibb Mid-career  
Female Investigator Grant  
2020 Mark Foundation Emerging Leader Award

---



**Daniel Makarov, MD (ECC)**  
2018 Prostate Cancer Foundation  
Young Investigator Award

# Emerging National Leadership



## **Shruti Naik, PhD (TIM)**

Regeneron New Investigator Award for Excellence in Cytokine & Interferon Research (2021)  
NIH Director's New Innovator Award (2020)  
2020 Packard Fellow for Science and Engineering  
2020 Pew Scholar & 2020 V Foundation Scholar Award

---



## **Michael Pacold, MD, PhD (CCB)**

2022 Pershing Square Sohn Cancer Research Alliance Prize & 2020 and 2022 Damon Runyon Rachleff Innovation Awards, 2020 MRA Young Investigator Award

---



## **Christopher Park, MD, PhD (CCB)**

2021 V Foundation Translational Research Award



## **Neville Sanjana, PhD (CGD)**

2018 AAAS Martin and Rose Wachtel Cancer Research Award, 2017 NIH New Innovator Award


---



## **Elaine Shum, MD (CGD)**

Lung Force Walk 2022 Medical Honoree, American Lung Association & Distinguished Young Investigator Research Award, 3<sup>rd</sup> Annual EGFR Resisters Research Summit (2021)

---



## **Jun Wang, PhD (TIM)**

2021 V Foundation Scholar Award  
2021 Mark Foundation Aspire Award


---



## **David Wise, MD, PhD (CGD)**

2018 Prostate Cancer Foundation Young Investigator Award

# Continuing Increase in Team Science





## IITs Based on PCC Science or Clinical Concepts

Trial	PI/Program	PCC Roles and Outcomes
*Phase Ib trial of canakinumab (anti-IL-1 $\beta$ ) + the anti-PD-1 inhibitor spartalizumab + gemcitabine and abraxane in pancreatic cancer	Oberstein/Bar-Sagi/Simeone (CCB)	GI ASCO Presentation; Led to arm in Precision Promise (PANCAN)
*Phase II Trial of ipilimumab/nivolumab/ tocilizumab in stage IV melanoma	Weber (TIM), Multicenter trial	ESMO Presentation; Led to Phase III Ipi/Nivo/Sarilumab/Relatlimab
*Phase Ib/Ila study of DKN-01 $\pm$ docetaxel in advanced prostate cancer	Wise (CGD)	ASCO Presentation; Phase II initiated
*Phase Ib study of ipilimumab/nivolumab/mocetinostat in stage III/IV melanoma	Weber (TIM)	<b>Melanoma Res</b>
*Phase Ib study of vitamin C in intermediate or high-risk MDS with TET2 mutations	Abdul Hay (CGD)	Closed to accrual, pending analysis
*Phase II study of AZD1775 $\pm$ cytarabine in AML, MDS, and myelofibrosis	Abdul Hay (CGD)	Closed to accrual, pending analysis
*Pilot study of gut microbiome modulation to enable efficacy of checkpoint-based immunotherapy in pancreatic adenocarcinoma	Cohen/Miller (ex-TIM)	Closed to accrual, pending analysis
*Phase II study of losartan/nivolumab + folfirinix/SBRT in localized pancreatic cancer (Stand Up to Cancer)	Oberstein/Kimmelman (CCB)	Closed to accrual, pending analysis
*Phase II study of high-dose post-transplant cyclophosphamide + bortezomib for prevention of GVHD following allogeneic HSCT	Al-Homsi (TIM)	Closed to accrual, pending analysis
*Phase II study of caffeine-based antifibrosis cream in breast cancer patients undergoing radiation therapy (ReDCoAT study)	Gerber (CGD)/Cronstein (CCB)	Open to accrual
Phase I trial of ipilimumab/nivolumab/ brentuximab in relapsed Hodgkin lymphoma (ECOG 4412)	Diefenbach (TIM); National PI	<b>Lancet Haematol</b> ; Led to Phase II and approval of BV-Nivo
Phase II ipilimumab/nivolumab in metaplastic breast cancer (Cohort #36 of SWOG 1609 Dual Anti-CTLA-4 and PD-1 blockade in rare tumors (DART))	Adams (TIM)	<b>Clin Cancer Res</b>
Pembrolizumab + gemcitabine + RT in muscle-invasive urothelial cancer	Balar (ex-TIM)	ASCO Oral Presentation; Led to a randomized Phase III Merck trial
Phase I study of nivolumab + ASTX727 in R/R DLBCL (ET-CTN, P10508)	Diefenbach (TIM)	Open to accrual

## Industry Sponsored Trials with PCC Faculty as National PI (\*Based on PCC Science)

Trial	PI/Program	PCC Roles and Outcomes
*Phase I/II trial of MRTX849 + TNO155 in tumors with KRAS G12C mutation	Sabari/Neel (CCB)	Closed to accrual; Pending analysis
Phase II trial of adjuvant pembrolizumab ± mRNA Vaccine in stage III/resected stage IV melanoma	Weber (TIM)	Closed to accrual; Phase III Randomized Trial planned (Merck-sponsored study)
Phase III Trial of dostarlimab in dMMR/MSI-H or MMRp/MSS endometrial cancer (GARNET)	Pothuri (CGD)	<b><i>J Immunother Cancer</i></b> FDA Approval
Phase III Trial of sotorasib in lung cancer with KRAS G12C mutation	Velcheti (CCB)	<b><i>N Engl J Med</i></b> ; FDA Approval
Phase I Trial of amivantamab in advanced NSCLC	Sabari (CCB)	ASCO Oral Presentation; <b><i>J Clin Oncol</i></b> FDA Approval
Phase I/II Trial of MRTX849 in all solid tumors and NSCLC	Sabari (CCB)	<b><i>Clin Cancer Res</i></b> ; <b><i>N Engl J Med</i></b> ; FDA Approval
Phase II of pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057)	Balar (ex-TIM)	<b><i>Lancet Oncol</i></b> FDA Approval
Phase II Trial of enfortumab vedotin after PD-1 and PD-L1 inhibitors in cisplatin-ineligible patients with urothelial carcinoma	Balar (ex-TIM)	<b><i>Lancet Oncol</i></b> FDA Approval

# Current Investigator Initiated Trials


Trial	PI/Program
A Phase I Study of Nivolumab in Combination with ASTX727 in NHL, HL, DLBCL <b>(ET-CTN)</b>	Diefenbach (TIM)
A Phase I/II Trial DNA-PK inhibitor M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Solid Tumors and Hepatobiliary Malignancies <b>(ET-CTN)</b>	Spencer (CGD)
Phase II Trial of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients	Chan (CCB)
A phase II, randomized, double blind, placebo controlled study of the safety and efficacy of a caffeine-based antifibrosis cream in patients with breast cancer undergoing radiation therapy	Gerber (CCB)
Phase II: Adaptive Treatment De-Escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma	Hu (CCB)

# PCC Researchers Impact FDA Approvals

Faculty	Drug	Disease	Approved
Balar	Sacituzumab govitecan (Trodelvy)	Bladder	2021
Balar	Enfortumab vedotin (Padcev)	Bladder	2021
Sabari	Amivantamab (Rybrevant)	NSCLC	2021
Velcheti	Sotorasib (Lumakras)	NSCLC	2021
Pothuri	Dostarlimab (Jemperli)	Endometrial	2021
Pothuri	Niraparib (Zejula)	Ovarian	2020
Mehnert	Pembrolizumab (Keytruda)	Melanoma (Stage IIB/C)	2021
Velcheti	Selpercatinib	RET positive NSCLC	2020
Velcheti	Pembrolizumab (Keytruda) + Chemotherapy	NSCLC	2018



# Clinical Trial Accruals and Quality Increased

Accruals to interventional treatment and non-interventional studies, all sites (2018-22)					
	2018	2019	2020	2021	2022
Interventional (treatment)	1113 (514)	1021 (562)	762 (458)	1143 (497)	1157 (622)
Non-interventional	3528	4629	4270	5667	7473



Therapeutic accruals by Phase \*through 11/30 and annualized

# Interventional Treatment Accruals Increased




Accruals for interventional (A) and non-interventional (B) studies (2018–2022) Long Island merged with PCC in 2019. \*Annualized

# Lung Cancer Center




# Center for Blood Cancers






# Pancreas Cancer Center



# Cutaneous Oncology Center




# Expanding Impact



Perlmutter Cancer Center comprises 59 centers, programs, and services across 37 sites throughout New York City and Long Island

**Perlmutter  
Cancer Center**

# Perlmutter Cancer Center of the Future: Envisioned Structure



**Perlmutter  
Cancer Center**